Prior to randomising patients, centres must have sent copies of their SSA approval, R&D approval, Site Agreement and completed Centre Registration Form (and CTA or equivalent if a non-UK centre) to the AML Trials Office.
AML16 Patient Record Book
AML16 Intensive Patient Record Book
AML16 Non-Intensive Patient Record Book
AML16 Randomisation Notepad
Randomisation Notepad Intensive 1st Randomisation
Randomisation Notepad Intensive 2nd Rand (Cons/Main)
Randomisation Notepad Non-Intensive LD Ara-C v LD Clofarabine v Sapacitabine
Other Trial Documenation
AML16 Change of Trial Staff Form
AML16 Serious Adverse Event Form
AML16 Trial Guides and Information
NCI Toxicity Criteria
AML16 PowerPoint Presentation (please contact AML Trials Office)
AML16 Important Reference Numbers and Dates
AML16 Lay Summary (please contact AML Trials Office)
AML16 Sample Requirements
AML16 Azacytadine - Gene methylation status assessment form
AML16 Online Randomisation Guide for External Users
AML16 Online Data Entry Guide for External Users
Per Patient Payments
There will not be any Per Patient Payments in the AML16 trial.